Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Milena Perez MakGilberto de Castro

Abstract

Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures. Case report. We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO. This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.

References

Jun 1, 1975·The British Journal of Radiology·D J HoskingW R Shortland-Webb
May 1, 1995·The Journal of Clinical Endocrinology and Metabolism·G E WilkinsG P Bondy
Apr 25, 2003·The New England Journal of Medicine·Kenneth B JonssonHarald Jüppner
Jun 3, 2004·Journal of the National Cancer Institute·Fred SaadUNKNOWN Zoledronic Acid Prostate Cancer Study Group
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paranee AuethavekiatJeffrey L Berenberg
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert E Coleman
Nov 27, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Casey L Cotant, Panduranga S Rao
Apr 15, 2011·Endocrine-related Cancer·William H ChongMichael T Collins

❮ Previous
Next ❯

Citations

Feb 9, 2013·The Journal of Clinical Endocrinology and Metabolism·David E LeafHarald Jüppner
Jan 10, 2014·Skeletal Radiology·Monica C KoplasMurali Sundaram
Sep 21, 2015·Annals of Diagnostic Pathology·Arturo Angeles-AngelesBraulio Martinez-Benitez
Mar 28, 2017·Endocrine-related Cancer·Georgios K DimitriadisAshley Grossman
Nov 28, 2015·International Journal of Surgical Pathology·Adrienne SauderDonghong Cai
Jun 25, 2014·The Journal of Clinical Endocrinology and Metabolism·Swati JadhavNalini S Shah
Jul 14, 2017·Nature Reviews. Disease Primers·Salvatore MinisolaMichael T Collins
Jul 6, 2019·Journal of Diabetes and Metabolic Disorders·Constantinos SavvaKamal Chokkalingam
Jun 7, 2020·Calcified Tissue International·Pablo FlorenzanoMichael T Collins
May 29, 2015·Oncotarget·Shu FengMichael Ittmann
Jul 19, 2019·BMJ Case Reports·Awo Akosua K LaymanSanjeev Shah
Feb 15, 2021·Annals of Nuclear Medicine·Ayako KatoKaori Togashi
Jun 21, 2021·Bone·Maria Luisa BrandiLothar Seefried
Jul 14, 2021·Journal of Bone and Mineral Metabolism·Nobuaki ItoSeiji Fukumoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.